Purple Biotech (PPBT) Other Non-Current Assets (2020 - 2025)
Purple Biotech (PPBT) reported Other Non-Current Assets of $5000.0 for Q4 2025, down 16.67% year-over-year from $6000.0 in Q4 2024, and down 16.67% on a QoQ basis from $6000.0 in Q4 2024.
Purple Biotech (PPBT) has 6 years of Other Non-Current Assets data on file, last reported at $5000.0 in Q4 2025.
- Quarterly Other Non-Current Assets fell 16.67% year-over-year to $5000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5000.0 (down 16.67% YoY) and the FY2025 annual result came in at $5000.0, down 16.67% from the prior year.
- Other Non-Current Assets retreated to $5000.0 in Q4 2025 per PPBT's latest filing, from $6000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $160000.0 in Q4 2021 and bottomed at $5000.0 in Q4 2025.
- The 5-year median for Other Non-Current Assets is $6000.0 (2023), against an average of $37400.0.
- The widest annual swing landed in 2021, when Other Non-Current Assets slumped 94.79%; it then changed 0.0% in 2024.
- Tracing PPBT's Other Non-Current Assets over 5 years: stood at $160000.0 in 2021, then sank by 93.75% to $10000.0 in 2022, then slumped by 40.0% to $6000.0 in 2023, then changed by 0.0% to $6000.0 in 2024, then slipped by 16.67% to $5000.0 in 2025.
- Per Business Quant, the three latest PPBT Other Non-Current Assets figures stand at $5000.0 (Q4 2025), $6000.0 (Q4 2024), and $6000.0 (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Purple Biotech | 3.58 Bn | 3.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2022 | 10,000.00 |
| Sep 30, 2022 | 2.64 Mn |
| Jun 30, 2022 | 2.64 Mn |
| Mar 31, 2022 | 2.66 Mn |
| Dec 31, 2021 | 160,000.00 |
| Sep 30, 2021 | 5.02 Mn |
| Jun 30, 2021 | 5.02 Mn |
| Mar 31, 2021 | 3.07 Mn |
| Dec 31, 2020 | 3.07 Mn |